Work

Trends in Dupilumab Utilization for the Treatment of Chronic Rhinosinusitis With Nasal Polyps

Year: 2024

Type: article

Abstract: M.J.C. serves as a consultant for 3-D Matrix (Newton, MA), Acclarent (Irving, CA), Medtronic (Jacksonville, FL), Neurent (Braintee, MA), and Lynx MD (Palo Alto, CA). A.U.L. serves as a consultant for AstraZeneca (Cambridge, UK), GlaxoSmithKline (Maharashtra, India), (Lyra Therapeutics (Watertown, MA), Medtronic (Dublin, IE), Neurent Medical (Galway, IE), Sanofi (Paris, France), Sound Health Systems (Los Altos, CA), and Stryker (Kalamazoo, MI). A.U.L. serves on the scientific advisory board for Maxwell Biosciences (Austin, TX). W.C.Y. serves as a consultant for Acclarent Inc. (Irving, CA), Aerin Medical (Mountain View, CA), and as a Speaker for Optinose Inc. (Yardley, PA). No disclosures for DX and JT.

Source: International Forum of Allergy & Rhinology

DOI: 10.1002/alr.23508

Authors: Daniel Xiao, Jason Talmadge, Martin J. Citardi, William C. Yao, Amber U. Luong

Institutions: The University of Texas Health Science Center at Houston, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases

Language: English

Topic: Sinusitis and nasal conditions

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4405550520

FWCI:

Cites: 6

Cited by:

Related to: 10